Aurinia Pharmaceuticals Inc
Closed
SectorHealthcare
18.63 3.9
Overview
Share price change
24h
Min
17.8
Max
19.19
Income | -176M 34M |
|---|---|
Sales | 591K 78M |
P/E Sector Avg | 8.051 50.958 |
EPS | 0.25 |
Profit margin | 44.212 |
Employees | 128 |
EBITDA | 2.7M 50M |
Recommendations | Buy |
|---|---|
12 Months Forecast | -12.36% downside |
Next Earnings | 30 lip 2026 |
|---|
Market Cap | 187M 2.2B |
|---|---|
Previous open | 14.73 |
Previous close | 18.63 |
News Sentiment
By Acuity
50%
50%
146 / 342 Ranking in Healthcare
Aurinia Pharmaceuticals Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
About Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.
